New imaging test may predict which breast cancer patients respond to hormone therapy
NCT ID NCT04573231
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a special PET/CT scan that looks for a protein called PSMA can help predict resistance to anti-androgen therapy in people with a specific type of metastatic breast cancer (HER2-negative, AR-positive). About 13 participants will receive an injection of a radioactive tracer and undergo imaging. The goal is to see if PSMA levels in tumors are linked to treatment resistance, which could help select patients for future therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-DCFPyL (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this could help identify which patients with this type of breast cancer might benefit from anti-androgen treatments, leading to more personalized therapy.
What could go wrong
This is a very small early-phase study (13 people) focused on imaging, not treatment. It may not lead to any change in patient care or outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin School of Medicine and Public Health
RECRUITINGMadison, Wisconsin, 53705, United States